Here's What Key Metrics Tell Us About Haemonetics (HAE) Q4 Earnings
The headline numbers for Haemonetics (HAE) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $0.90 per share a year ago.
Gear Up for Haemonetics (HAE) Q4 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Haemonetics (HAE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is it Apt to Retain HAE Stock in Your Portfolio for Now?
Strong prospects for the Hospital Business and the robust NexSys PCS system bode well for Haemonetics.
Astria Therapeutics: A High-Conviction Bet On HAE
Astria Therapeutics' strong cash position and efficient spending provide a financial runway through mid-2027, reducing dilution risk and supporting pivotal trials for navenibart and STAR-0310. Navenibart, targeting hereditary angioedema, shows promising Phase 1b/2 data with a 90-95% reduction in attack rates, positioning it as a potential best-in-class treatment. STAR-0310, aimed at atopic dermatitis, leverages OX40 inhibition and YTE half-life extension technology, though it faces stiff competition and must prove differentiation.
HAE Q3 Earnings In Line, '25 Sales View Cut, Stock Up in Aftermarket
Haemonetics' third-quarter fiscal 2025 results reflect the positive effects of the company's long-range plan with meaningful earnings growth and margin expansion.
Haemonetics Corporation (HAE) Q3 2025 Earnings Call Transcript
Haemonetics Corporation (NYSE:HAE ) Q3 2025 Earnings Conference Call February 6, 2025 8:30 AM ET Company Participants Olga Guyette - Vice President, Investor Relations and Treasury Christopher Simon - President and Chief Executive Officer James D'Arecca - EVP and Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuho Financial Group Marie Thibault - BTIG David Turkaly - Citizens JMP Andrew Cooper - Raymond James Mike Matson - Needham & Company Craig Bijou - Bank of America Securities Michael Petusky - Barrington Research Larry Solow - CJS Securities Operator Good day, and welcome to the Haemonetics Third Quarter Fiscal Year 2025 Conference Call and Webcast. At this time, all participants are in a listen-only-mod.
Haemonetics (HAE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Haemonetics (HAE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Haemonetics (HAE) Q3 Earnings Meet Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.19 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.04 per share a year ago.
Here's Why Haemonetics (HAE) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
HAE or ABT: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?
